IL1B and atherosclerosis: Most of the proposed interventions are expected to cause direct or indirect inhibition of the nucleotide‐binding domain leucine‐rich repeat and pyrin domain containing receptor 3 (NLRP3)‐IL‐1β/‐IL‐6 axis, because there is strong evidence for its involvement in atherosclerosis.